Back to top
more

Zoetis (ZTS)

(Real Time Quote from BATS)

$172.97 USD

172.97
1,485,554

+2.60 (1.53%)

Updated Nov 7, 2024 12:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Acadia Healthcare (ACHC) Buys Real Estate to Expand in Chicago

by Zacks Equity Research

Acadia Healthcare (ACHC) purchases real estate in Illinois to serve the local communities with better healthcare facilities.

    Ensign Group (ENSG) Hikes Dividend to Share More Profits

    by Zacks Equity Research

    Ensign Group's (ENSG) dividend hike reflects its intention to enhance shareholders' value supported by its strong financial position.

    The Zacks Analyst Blog Highlights: Walmart, Honeywell, Zoetis, Colgate-Palmolive and IDEXX Lab

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Walmart, Honeywell, Zoetis, Colgate-Palmolive and IDEXX Lab

    Sheraz Mian headshot

    Top Stock Reports for Walmart, Honeywell & Zoetis

    by Sheraz Mian

    Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Honeywell International Inc. (HON), and Zoetis Inc. (ZTS).

    Kanishka Das headshot

    Zoetis' (ZTS) Earnings and Revenues Surpass Estimates in Q3

    by Kanishka Das

    Zoetis' (ZTS) earnings and revenues beat estimates in the third quarter of 2021. The company raised its financial guidance for 2021.

    Zoetis (ZTS) Beats Q3 Earnings and Revenue Estimates

    by Zacks Equity Research

    Zoetis (ZTS) delivered earnings and revenue surprises of 13.64% and 2.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More

    by Zacks Equity Research

    Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.

    Is a Surprise Coming for Zoetis (ZTS) This Earnings Season?

    by Zacks Equity Research

    Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

    by Zacks Equity Research

    Sector ETF report for IHE

    Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    Viatris' (VTRS) Q3 earnings might have gained from the solid performance of Viagra, Dymista, and the Thrombosis portfolio.

    Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

    by Zacks Equity Research

    Zoetis (ZTS) is set to report earnings and revenues, and provide updates on its diversified product portfolio when it releases third-quarter 2021 results.

    Humana (HUM) to Post Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    Humana's (HUM) third-quarter earnings are expected to have gained from higher revenues and a solid contribution from its Retail and Healthcare Services segments.

    4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates

    by Zacks Equity Research

    Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

    Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

    by Zacks Equity Research

    Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

    by Zacks Equity Research

    The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

    Why Zoetis (ZTS) Could Beat Earnings Estimates Again

    by Zacks Equity Research

    Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

    by Zacks Equity Research

    Sector ETF report for XPH

    The Zacks Analyst Blog Highlights: Home Depot, Salesforce, Pfizer, Sony and Zoetis

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Home Depot, Salesforce, Pfizer, Sony and Zoetis

    Sheraz Mian headshot

    Top Research Reports for Home Depot, salesforce & Pfizer

    by Sheraz Mian

    Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), salesforce.com, inc. (CRM), and Pfizer Inc. (PFE).

    COLL vs. ZTS: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    COLL vs. ZTS: Which Stock Is the Better Value Option?

    Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for FTCS

    Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Zoetis (ZTS) earnings and revenues beat estimates in the second quarter of 2021. The company raised its financial guidance for 2021.

    Zoetis (ZTS) Surpasses Q2 Earnings and Revenue Estimates

    by Zacks Equity Research

    Zoetis (ZTS) delivered earnings and revenue surprises of 10.19% and 6.30%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN

    by Zacks Equity Research

    Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.

    Why Earnings Season Could Be Great for Zoetis (ZTS)

    by Zacks Equity Research

    Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.